Assessing Cardiovascular Target Attainment in Type 2 Diabetes Mellitus Patients in Tertiary Diabetes Center in Romania

Introduction: Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) share a bidirectional link, and the innovative antidiabetic molecules GLP-1 Ras and SGLT-2is have proven cardiac and renal benefits, respectively. This study aimed to evaluate CV risk categories, along with lipid-lowering...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Vol. 17; no. 9; p. 1249
Main Authors: Salmen, Teodor, Pietrosel, Valeria-Anca, Reurean-Pintilei, Delia, Iancu, Mihaela Adela, Cimpeanu, Radu Cristian, Bica, Ioana-Cristina, Dumitriu-Stan, Roxana-Ioana, Potcovaru, Claudia-Gabriela, Salmen, Bianca-Margareta, Diaconu, Camelia-Cristina, Cretoiu, Sanda Maria, Stoian, Anca Pantea
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 01.09.2024
MDPI
Subjects:
Antidiabetics
Atherosclerosis
cardio-renal protection
cardiovascular disease
Cardiovascular diseases
Care and treatment
Complications and side effects
Demographic aspects
Diabetes
Diabetic neuropathy
Diagnosis
Disease
Exercise
Fatalities
Glucose
LDL-cholesterol
Lipids
Metabolic disorders
Mortality
Oxidative stress
Patients
risk
Risk factors
statin
Statins
Type 2 diabetes
type 2 diabetes mellitus
Weight control
Romania
LDL-cholesterol
cardiovascular disease
statin
type 2 diabetes mellitus
risk
cardio-renal protection
sodium-glucose co-transporter-2 inhibitors
glucagon-like peptide-1 receptor agonists
ISSN:1424-8247, 1424-8247
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) share a bidirectional link, and the innovative antidiabetic molecules GLP-1 Ras and SGLT-2is have proven cardiac and renal benefits, respectively. This study aimed to evaluate CV risk categories, along with lipid-lowering and antidiabetic treatments, in patients with T2DM from a real-life setting in Romania. Material and Methods: A cross-sectional evaluation was conducted on 405 consecutively admitted patients with T2DM in an ambulatory setting, assessing them according to the 2019 ESC/EAS guidelines for moderate, high, and very high CV risk categories. Results: The average age of the group was 58 ± 9.96 years, with 38.5% being female. The mean HbA1C level was 7.2 ± 1.7%. Comorbidities included HBP in 88.1% of patients, with a mean SBP and DBP of 133.2 ± 13.7 mm Hg and 79.9 ± 9 mm Hg, respectively, and obesity in 66.41%, with a mean BMI of 33 ± 6.33 kg/m2. The mean LDL-C levels varied by CV risk category: 90.1 ± 34.22 mg/dL in very high risk, 98.63 ± 33.26 mg/dL in high risk, and 105 ± 37.1 mg/dL in moderate risk. Prescribed treatments included metformin (100%), statins (77.5%), GLP-1 Ras (29.4%), and SGLT-2is (29.4%). Conclusions: In Romania, patients with T2DM often achieve glycemic control targets but fail to meet composite targets that include glycemic, BP, and lipid control. Additionally, few patients benefit from innovative glucose-lowering therapies with proven cardio-renal benefits or from statins.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1424-8247
1424-8247
DOI:10.3390/ph17091249